Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

OPERATING LEASES (Tables)

9 Months Ended

Sep. 30, 2021

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

In accordance with ASC 842, the components of lease expense were as follows:

	Nine Months ended September 30,				Three Months ended September 30,
	2021		2020		2021		2020
Operating lease expense	$	24,094	$	-	$	18,070	$	-
Short term lease cost	$	-	$	-	$	-	$	-
Total lease expense	$	24,094	$	-	$	18,070	$	-

In accordance with ASC 842, other information related to leases was as follows:

Nine Months ended September 30,		2021			2020
Operating cash flows from operating leases	$	9,131		$	-
Cash paid for amounts included in the measurement of lease liabilities	$	9,131		$	-

Weighted-average remaining lease term—operating leases		4.92 years			-
Weighted-average discount rate—operating leases		10	%		-

In accordance with ASC 842, maturities of operating lease liabilities as of September 30, 2021 were as follows:

Year ending:	Operating Lease
2021 (remaining three months)	$	11,911
2022		72,714
2023		74,895
2024		77,142
2025		79,456
Thereafter		54,225
Total undiscounted cash flows	$	370,342

Reconciliation of lease liabilities:
Weighted-average remaining lease terms		4.92 years
Weighted-average discount rate		10	%
Present values	$	291,331

Lease liabilities—current		38,524
Lease liabilities—long-term		252,807
Lease liabilities—total	$	291,331

Difference between undiscounted and discounted cash flows	$	79,011